Summit Therapeutics Inc. announced that Upon the closing of the License Agreement, the Board of Directors (the Board) of the Company appointed Dr. Yu (Michelle) Xia to serve as a member of the Board pursuant to the terms of the License Agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.25 USD | +9.42% | +2.61% | +216.09% |
06-03 | Sector Update: Health Care Stocks Steady Premarket Monday | MT |
06-03 | Stifel Adjusts Summit Therapeutics Price Target to $14 From $8, Maintains Buy Rating | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+216.09% | 5.79B | |
+16.93% | 123B | |
+17.01% | 111B | |
-7.23% | 23.63B | |
+2.62% | 22.58B | |
-14.73% | 17.26B | |
-6.79% | 17.6B | |
-37.63% | 17.61B | |
+2.17% | 13.55B | |
+24.42% | 11.34B |
- Stock Market
- Equities
- SMMT Stock
- News Summit Therapeutics Inc.
- Summit Therapeutics Inc. Appoints Yu Xia as Member of the Board